

Application No.: 10/779,532
Applicants: Green et al.

REMARKS

The Amendments to the Specification

Applicants have amended the specification to add a Sequence Listing. Support for SEQ ID NOS: 1-3 in the Sequence Listing may be found on page 74, lines 25 and 28 and on page 77, line 5.

Applicants have amended the specification by providing replacement page 77. Replacement page 77 is identical to originally-filed page 77 except that it provides a sequence identifier (SEQ ID NO: 3) for the EGF receptor peptide sequence.

None of these amendments adds new matter. Their entry is requested.

Response to the Notice to Comply

The Notice states that the application fails to comply with the requirements of 37 C.F.R. §§1.821-1.825. Specifically, the Notice states that the application does not contain a paper copy of a Sequence Listing or a computer readable form (CRF) of the Sequence Listing. The Notice further states that a CRF copy and paper copy of the Sequence Listing must be submitted, as well as a statement that the content of the paper and CRF copies of the Sequence Listing are the same and contain no new matter.

Applicants provide herewith a paper copy of a Sequence Listing, a CRF of the Sequence Listing and a statement that the content of the paper and CRF copies of the Sequence Listing are the same and contain no new matter.

Application No.: 10/779,532
Applicants: Green et al.

Conclusion

Applicants request that the Examiner enter the above amendments, consider the accompanying arguments, and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,

Karen E. Brown

Karen E. Brown
Registration No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617) 444-6168
Fax.: (617) 444-6483